Evidence map›Paper›PMID 33608522›Full record

ArticleNature communications2021

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19.

Adam K Wheatley, Jennifer A Juno, Jing J Wang, Kevin J Selva, Arnold Reynaldi, Hyon-Xhi Tan, Wen Shi Lee, Kathleen M Wragg, Hannah G Kelly, Robyn Esterbauer and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 242 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
242citing papers in PubMed, 6 pooled it
24.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

242 citing papers in PubMed, 6 syntheses or guidelines pooled it, 407 citations in OpenAlex.

  1. Pooled it
  2. Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. HLA-B*15:01-positive severe COVID-19 patients lack CD8Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  19. Broad neutralizing antibody response of a monomeric spike-based SARS-CoV-2 bivalent vaccine against diverse variants.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  20. Review

182 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 1 country.

Adam K Wheatley *Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0002-5593-9387
Jennifer A Juno *Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0002-9072-1017
Jing J Wang *Department of Immunology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Kevin J SelvaDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Arnold ReynaldiKirby Institute, University of New South Wales, Kensington, NSW, Australia.ORCID 0000-0002-5529-5542
Hyon-Xhi TanDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Wen Shi LeeDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0001-7285-4054
Kathleen M WraggDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Hannah G KellyDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Robyn EsterbauerDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0002-7091-0048
Samantha K DavisDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0002-6197-4277
Helen E KentDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Francesca L MordantDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0002-3754-2642
Timothy E SchlubKirby Institute, University of New South Wales, Kensington, NSW, Australia.ORCID 0000-0001-7746-9649
David L GordonDepartment of Microbiology and Infectious Diseases, Flinders University and SA Pathology, Flinders Medical Centre, Adelaide, SA, Australia.
David S KhouryKirby Institute, University of New South Wales, Kensington, NSW, Australia.ORCID 0000-0002-2663-1551
Kanta SubbaraoDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0003-1713-3056
Deborah CromerKirby Institute, University of New South Wales, Kensington, NSW, Australia.
Tom P GordonDepartment of Immunology, College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Amy W ChungDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.ORCID 0000-0003-0020-9704
Miles P DavenportKirby Institute, University of New South Wales, Kensington, NSW, Australia.ORCID 0000-0002-4751-1831
Stephen J KentDepartment of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. skent@unimelb.edu.au.ORCID 0000-0002-8539-4891
The University of Melbourne · AUAustralian Research Council · AUUNSW Sydney · AUSouth Australia Pathology · AUFlinders University · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Here, we show a comprehensive profile of antibody, B cell and T cell dynamics over time in a cohort of patients who have recovered from mild-moderate COVID-19. Binding and neutralising antibody responses, together with individual serum clonotypes, decay over the first 4 months post-infection. A similar decline in Spike-specific CD4

Indexed as

Antibody FormationImmunity, CellularImmunologic MemoryAntibodies, NeutralizingAntibodies, ViralB-LymphocytesCD4-Positive T-LymphocytesCOVID-19HumansImmunoglobulin GLongitudinal StudiesModels, TheoreticalNeutralization TestsT-Lymphocytes, Helper-InducerAntibodies, NeutralizingAntibodies, ViralImmunoglobulin G

Identifiers

PMID33608522
PMCPMC7896046
OpenAlexW3131938123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.